Literature DB >> 18849487

Relationship between monoclonal gammopathy of undetermined significance and radiation exposure in Nagasaki atomic bomb survivors.

Masako Iwanaga1, Masuko Tagawa, Kunihiro Tsukasaki, Tatsuki Matsuo, Ken-ichi Yokota, Yasushi Miyazaki, Takuya Fukushima, Tomoko Hata, Yoshitaka Imaizumi, Daisuke Imanishi, Jun Taguchi, Sabro Momita, Shimeru Kamihira, Masao Tomonaga.   

Abstract

Radiation exposure is a possible predisposing factor for monoclonal gammopathy of undetermined significance (MGUS), but the association has been uncertain. We investigated the relationship between radiation exposure and MGUS prevalence by using data from the M-protein screening for Nagasaki atomic bomb survivors between 1988 and 2004. Radiation exposure was assessed by exposure distance from the hypocenter and exposure radiation dose. We computed prevalence ratios (PRs) and the 95% confidence intervals (CIs) adjusting for exposure age and sex. A total of 1082 cases of MGUS were identified from 52 525 participants. MGUS prevalence was significantly higher in people exposed at distance within 1.5 km than beyond 3.0 km (PR, 1.4; 95% CI, 1.1-1.9) among those exposed at age 20 years or younger, but it was not found among those exposed at age 20 years or older. MGUS prevalence was also significantly higher in people exposed to more than 0.1 Gy than those exposed to less than 0.01 Gy (PR, 1.7; 95% CI, 1.0-2.8) among those exposed at age 20 years or younger. Thus, people exposed at younger age exhibited a significantly high risk of MGUS when exposed to a high radiation dose. There was no clear association between radiation exposure and the malignant progression of MGUS. Further detailed analysis is needed.

Entities:  

Mesh:

Year:  2008        PMID: 18849487     DOI: 10.1182/blood-2008-05-159665

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  11 in total

Review 1.  Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.

Authors:  Robert A Kyle; S Vincent Rajkumar
Journal:  Curr Hematol Malig Rep       Date:  2010-04       Impact factor: 3.952

Review 2.  Second malignancies after multiple myeloma: from 1960s to 2010s.

Authors:  Anish Thomas; Sham Mailankody; Neha Korde; Sigurdur Y Kristinsson; Ingemar Turesson; Ola Landgren
Journal:  Blood       Date:  2012-02-06       Impact factor: 22.113

Review 3.  Advances in understanding monoclonal gammopathy of undetermined significance as a precursor of multiple myeloma.

Authors:  Brendan M Weiss; W Michael Kuehl
Journal:  Expert Rev Hematol       Date:  2010-04       Impact factor: 2.929

Review 4.  Management of monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM).

Authors:  Robert A Kyle; S Vincent Rajkumar
Journal:  Oncology (Williston Park)       Date:  2011-06       Impact factor: 2.990

5.  Prevalence of monoclonal gammopathy of undetermined significance in Thailand.

Authors:  Phandee Watanaboonyongcharoen; Thanyaphong Na Nakorn; Ponlapat Rojnuckarin; Panisinee Lawasut; Tanin Intragumtornchai
Journal:  Int J Hematol       Date:  2012-01-12       Impact factor: 2.490

Review 6.  An update on monoclonal gammopathy and neuropathy.

Authors:  Sindhu Ramchandren; Richard A Lewis
Journal:  Curr Neurol Neurosci Rep       Date:  2012-02       Impact factor: 5.081

7.  Prospects and status of the dosimetry system for atomic bomb survivor cohort study conducted at Research Institute for Radiation Biology and Medicine of Hiroshima University.

Authors:  Seiko Hirota; Hiroshi Yasuda; Hideshi Kawakami; Shinji Yoshinaga
Journal:  J Radiat Res       Date:  2021-05-05       Impact factor: 2.724

8.  Prevalence and type of monoclonal gammopathy of undetermined significance in an apparently healthy Nigerian population: a cross sectional study.

Authors:  A Lawretta Onwah; Titilope A Adeyemo; Adewumi Adediran; Sarah O Ajibola; Alani S Akanmu
Journal:  BMC Blood Disord       Date:  2012-06-28

9.  Unusual case of simultaneous presentation of plasma cell myeloma, chronic myelogenous leukemia, and a jak2 positive myeloproliferative disorder.

Authors:  J Maerki; G Katava; D Siegel; J Silberberg; P K Bhattacharyya
Journal:  Case Rep Hematol       Date:  2014-10-15

10.  Evaluation of HBV, HCV, and HIV seroprevalence in patients with plasma cell disorders.

Authors:  Duygu Mert; Alparslan Merdin; Merih Kizil Çakar; Mehmet Sinan Dal; Fevzi Altuntaş
Journal:  Medicine (Baltimore)       Date:  2020-08-21       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.